Replies to post #84961 on Biotech Values

[DewDiligence]

VNDA probrably spent near $200m over the last XX years developing [Iloperidone]…

How do you figure that? I would guess that VNDA’s development expenses have been a small fraction of your figure.

why wouldnt [VNDA] publish the revenue share?

This deal does not have revenue sharing, but rather royalties on sales. The royalty terms in these kinds of deals are rarely disclosed.